# Retatrutide: Research Overview — Private Peptides > A clinical-briefing read on retatrutide (LY3437943), the investigational GIP/GLP-1/glucagon triple agonist: mechanism, Phase 2 trial results, and the documented cautions ahead of Phase 3. An investigational triple agonist at GLP-1, GIP, and glucagon receptors, with Phase 2 weight-loss figures larger than any approved incretin drug — and no regulatory approval anywhere as of mid-2026. ## The short version Retatrutide, also designated **LY3437943**, is a single engineered peptide built to activate three separate metabolic receptors at once: GLP-1, GIP, and glucagon. It is in Phase 3 clinical trials sponsored by Eli Lilly and is **not approved** by the FDA or any regulator as of mid-2026. Every efficacy and safety figure on this page comes from Phase 1 and Phase 2 studies; Phase 3 (TRIUMPH) results are not yet published. In a 48-week Phase 2 obesity trial, the highest studied dose produced a mean **-24.2% body-weight change** versus -2.1% with placebo [16] — the largest Phase 2 figure reported for any incretin-class compound. In a Phase 2 diabetes trial, the same dose lowered HbA1c by -2.02% at 24 weeks and body weight by 16.94% at 36 weeks [17]. A liver-disease substudy found 86% of participants at the top dose reached normal liver fat by 24 weeks [15]. This page reports the mechanism and the trial record; it recommends no dose and provides no reconstitution or administration guidance. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, acylated with a C20 fatty-diacid arm that drives strong albumin binding, extending its half-life enough to support once-weekly subcutaneous dosing in the trials that have tested it. Molecular formula C221H342N46O68 (free acid). It is a **triple agonist**: one molecule engaging three receptors — GLP-1R, GIPR, and the glucagon receptor (GCGR). Cryo-EM structural work resolved how it binds all three at atomic resolution and found the engagement is deliberately uneven: roughly 8.9-fold more potent than native GIP at the GIP receptor, but only 0.3-fold and 0.4-fold as potent as the endogenous hormones at the glucagon and GLP-1 receptors respectively. The binding loop that shapes receptor selectivity (ECL1) adopts a rigid alpha-helix at GLP-1R and GCGR but a flexible loop at GIPR — structural evidence that this molecule was engineered to engage three targets differently, not identically [14]. ## How it works Retatrutide inherits the GLP-1/GIP pharmacology already established in approved incretin drugs — glucose-dependent insulin secretion, slowed gastric emptying, appetite suppression via hypothalamic and brainstem circuits — and adds a third lever: controlled glucagon receptor activation. Glucagon normally tells the liver to release stored glucose, which is why GLP-1 drugs have to work around it. Here, in the context of simultaneous GLP-1/GIP-driven insulin support, mild glucagon receptor activity instead appears to raise energy expenditure through brown-adipose-tissue thermogenesis and fatty-acid oxidation, with limited net effect on blood glucose. The practical logic: the GLP-1/GIP arms reduce intake, the glucagon arm raises expenditure. A 2025 review frames the resulting ~24% Phase 2 weight loss as a step-change rather than an incremental gain over dual-agonist therapy [13]. Cardiovascular and renal implications of this three-receptor pharmacology are the subject of dedicated ongoing outcome trials. ## What the research shows *Structural basis for triple agonism (2024).* Cryo-EM resolved retatrutide's binding to GLP-1R, GIPR, and GCGR complexes at 2.68, 3.26, and 2.84 angstrom resolution, confirming genuinely differential engagement across the three: roughly 8.9-fold above native GIP at GIPR, but only 0.3-fold and 0.4-fold versus native hormones at GCGR and GLP-1R [14]. *Phase 2 obesity trial (2023).* In 338 adults with obesity over 48 weeks, once-weekly retatrutide at 12 mg produced -24.2% mean body weight versus -2.1% with placebo. GI adverse events were dose-related and mostly mild-to-moderate; a dose-dependent rise in resting heart rate peaked around week 24 [16]. *Phase 2 type 2 diabetes trial (2023).* In 281 adults with type 2 diabetes over 36 weeks, 12 mg lowered HbA1c by -2.02% versus -0.01% with placebo at 24 weeks and reduced body weight by 16.94% versus 3.00% with placebo at 36 weeks. GI adverse events occurred in 35% of participants; no severe hypoglycemia and no deaths were reported [17]. *Metabolic liver disease substudy (2024).* In 98 adults with obesity or overweight and metabolic dysfunction-associated steatotic liver disease, retatrutide 12 mg reduced relative liver fat by 82.4% at 24 weeks, with 86% of participants reaching normal (under 5%) liver fat — a reduction sustained to 48 weeks [15]. *Narrative synthesis (2025).* A review of the Phase 1/2 program describes the ~24% weight loss at 12 mg/48 weeks as a step-change versus prior incretin agents, lays out the glucagon-driven energy-expenditure hypothesis, and summarizes the GI and heart-rate safety signals alongside the ongoing Phase 3 TRIUMPH program [13]. ## Reported effects, cautions & safety People describing retatrutide use in research-peptide communities report a pattern broadly consistent with the GLP-1/GIP drug class, plus some features attributed to the added glucagon arm. These reports are **anecdotal, not clinical evidence** — self-reported, without confirmed dosing or clinical oversight, and not a substitute for the trial data above. *Reported benefits (anecdotal, not clinical evidence):* Near-total quieting of food-related thoughts — described as more complete than with other incretin-class compounds — is the most consistent theme. Rapid, pronounced weight reduction is frequently reported, broadly tracking the Phase 2 trajectory. A subset describe a distinct warmth or mild thermogenic sensation, widely attributed in community discussion to the glucagon receptor arm. Mood uplift and a lighter relationship with food are occasionally mentioned. *Reported adverse effects (anecdotal, not clinical evidence):* Nausea in the hours after injection, peaking 4-8 hours post-dose and most pronounced in the first weeks, is the most common complaint. An elevated resting heart rate — some describe 5-15 bpm increases on wearables — is a recurring theme that maps onto the dose-dependent heart-rate signal documented in Phase 2. Sulfur burps, constipation, early fatigue, occasional injection-site itching, and sleep disturbance are also described. *What to watch — cited cautions from the literature:* - **Unverified supply outside clinical trials.** Retatrutide is not approved; material obtained outside a registered trial cannot be confirmed to be authentic retatrutide at the stated concentration. The FDA issued more than 50 warning letters to vendors of retatrutide-labeled products in 2025 [13][16]. - **Dose-dependent gastrointestinal effects.** Nausea affected up to 45% of participants at the highest Phase 2 dose and drove an 18% discontinuation rate at that level; there is no dose-escalation oversight outside a clinical protocol [16]. - **Dose-dependent heart-rate increase.** Phase 2 data show mean increases of roughly 5-7 bpm at the highest doses, peaking around week 24; a dedicated cardiovascular outcomes trial is ongoing and has not reported results [16]. - **Hypoglycemia risk when combined with insulin or sulfonylureas.** GLP-1/GIP-driven insulin augmentation compounds the effect of exogenous insulin or sulfonylureas, and without clinical monitoring this interaction is harder to detect and correct [17]. - **Lean-mass reduction accompanies fat loss.** Body-composition data confirm an absolute reduction in lean mass alongside fat loss; the ratio looks more favorable than older bariatric benchmarks, but the absolute loss is still clinically meaningful in rapid-loss contexts. - **Long-term outcomes remain unknown.** The Phase 3 program, along with dedicated cardiovascular and kidney outcome trials, is still underway; no long-term safety or durability data exist yet, and prior GLP-1-class evidence suggests meaningful weight regain after stopping. ## Where it fits in Metabolic & Weight Research Retatrutide sits at the far end of this desk's frame — the fully engineered, deliberately multi-target answer to a question [AOD-9604](/aod-9604) and [MOTS-c](/mots-c) approach indirectly. It has the most structured human trial program of the three and, so far, the largest reported weight-loss effect — but it is also the only one still entirely inside the investigational stage, with Phase 3 results not yet reported. Reading it after the other two clarifies the trade this whole frame is built around: mechanistic ambition against maturity of human proof. See the [comparison page](/compare) for the direct read. ![Retatrutide research illustration — abstract triple-receptor pathway motifs in magenta](/images/retatrutide.webp) --- Private Peptides is filed like a clinician's briefing, not a chart note: evidence in, strength labeled, and no dose is ever recommended.